A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment

BACKGROUND: Immunotherapy is an emerging cancer therapy with potential great success; however, immune checkpoint inhibitor (e.g., anti-PD-1) has response rates of only 10–30% in solid tumor because of the immunosuppressive tumor microenvironment (TME). This affliction can be solved by vascular norma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Cheng-Liang, Chou, Han-Yu, Lien, Hui-Wen, Yeh, Chia-An, Wang, Jing-Rong, Chen, Chung-Hsing, Fan, Chi-Chen, Hsu, Chih-Ping, Kao, Ting-Yu, Ko, Tai-Ming, Lee, Alan Yueh-Luen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870840/
https://www.ncbi.nlm.nih.gov/pubmed/35895109
http://dx.doi.org/10.1007/s00262-022-03255-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870840/
https://www.ncbi.nlm.nih.gov/pubmed/35895109
http://dx.doi.org/10.1007/s00262-022-03255-9

Ejemplares similares